Bora Pharmaceuticals Completes Acquisition of GSK’s Canadian Facility

December 1, 2020
BioPharm International Editors

Originally announced in March 2020, the acquired facility will be Bora’s first North American manufacturing facility and will serve as its North American headquarters.

Bora Pharmaceuticals announced on Dec. 1, 2020 that it has completed its acquisition of GlaxoSmithKline (GSK)’s Mississauga, Ontario, Canada facility.

Originally announced in March 2020, the acquired facility will be Bora’s first North American manufacturing facility and will serve as its North American headquarters, a company press release said. The new facility will allow Bora to expand its range of dosage forms while it works to supply formulation development and manufacturing services globally.

“Completing the acquisition marks a major step in our expansion into North America, bringing us closer to many of our current and future customers,” said Bobby Sheng, CEO of Bora Pharmaceuticals, in the press release. “The Mississauga site strengthens our existing state-of-the-art manufacturing network, broadening our capabilities and almost doubling our number of talented colleagues, so that we can continue to support the current and future needs of our customers.”

Source: Bora